Jeffrey Conn

June 8, 2022

VUSM faculty honored with emerita or emeritus status

Vanderbilt University recently honored several faculty members for their years of service and bestowed on them the title of emeritus or emerita faculty. Among them were 15 from the School of Medicine.

By VUMC News and Communications
October 22, 2020

Lindsley to direct Center for Neuroscience Drug Discovery

Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.

By VUMC News and Communications
Max Joffe, PhD, left, P. Jeffrey Conn, PhD, and colleagues are studying a new class of antidepressants that may relieve symptoms more rapidly and with fewer side effects.
November 21, 2019

Study explores potential new class of antidepressants

Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.

By Bill Snyder
July 12, 2018

Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies

Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.

By VUMC News and Communications
January 18, 2018

Investigators eye new target for treating movement disorders

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

By Bill Snyder
Istock image of neurons in the brain
January 8, 2018

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

By Bill Snyder
December 7, 2017

Vanderbilt researchers’ papers among those most cited

Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder
October 12, 2017

Award honors Conn’s mental health research contributions

P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health.
By Bill Snyder
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
By Bill Snyder
September 15, 2016

Researchers eye potential schizophrenia ‘switch’

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
By Bill Snyder
October 29, 2015

Compound developed at VUMC may delay Huntington’s disease

A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder.
By Bill Snyder
October 8, 2015

Five VUMC faculty members on list of most frequently cited researchers

Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others.
By Bill Snyder
May 7, 2015

Findings reveal new target in quest to ease schizophrenia

Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
By Bill Snyder
1 2 3